Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedAppWAR:MDA -12.05%39 EV-to-EBITDA is 46.98 as of Aug. 09, 2026, which is 176% above its 10-year median of 17.03. GuruFocus rates WAR:MDA with a GF Score™ of 39/100 and a GF Value™ of zł0.24 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 510 Healthcare Providers & Services companies, MedApp ranks worse than 91.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MedApp's enterprise value is zł46.89 Mil.
MedApp's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was zł1.00 Mil. Therefore, MedApp's EV-to-EBITDA for today is 46.98.
The historical rank and industry rank for MedApp's EV-to-EBITDA or its related term are showing as below:
WAR:MDA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -476.39 Med: 17.03 Max: 558.42
Current: 46.98
During the past 13 years, the highest EV-to-EBITDA of MedApp was 558.42. The lowest was -476.39. And the median was 17.03.
WAR:MDA's EV-to-EBITDA is ranked worse than 91.76% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs WAR:MDA: 46.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-09), MedApp's stock price is zł0.1715.
MedApp's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.004. Therefore, MedApp's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MedApp's share price for today is zł0.1715.
MedApp's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MedApp's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MDA vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, MedApp's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedApp EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MedApp's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MedApp's EV-to-EBITDA falls into.
MedApp's current Enterprise Value is zł46.89 Mil.
MedApp's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł1.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedApp (WAR:MDA) has a EV-to-EBITDA of 46.98 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MedApp. This is 176% above median its historical median of 17.03. According to the industry distribution chart, MedApp ranks #468 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 91.8%.
Is MedApp's EV-to-EBITDA too high?
MedApp's current EV-to-EBITDA of 46.98 is 176% above median its 10-year median of 17.03. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.92. MedApp's value of 46.98 is 330.2% above this industry median. Based on the distribution chart, MedApp ranks #468 out of 510 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, MedApp has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MedApp's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MedApp ranks #468 out of 510 companies for EV-to-EBITDA. This places MedApp in the lower half of its industry. The industry median EV-to-EBITDA is 10.92. MedApp's value of 46.98 is 330.2% above this benchmark. While the company's 10-year median is 17.03 vs. the industry median of 10.92, MedApp has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedApp's current EV-to-EBITDA of 46.98 is 330.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MedApp. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedApp's current EV-to-EBITDA is 46.98, which is 176% above median its own 10-year median of 17.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedApp stock overvalued right now?
Based on GuruFocus' analysis, MedApp (WAR:MDA) is currently considered Modestly Undervalued. The stock's GF Value™ is zł0.24, compared to a current price of zł0.17 — trading 28.5% below its estimated fair value. The current EV-to-EBITDA is 46.98, which is 176% above median its 10-year median of 17.03 and 330.2% above the Healthcare Providers & Services industry median of 10.92. MedApp's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MedApp (WAR:MDA), the current EV-to-EBITDA is 46.98 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedApp (WAR:MDA) Overvalued in 2026?
Based on GuruFocus' analysis, MedApp stock appears to be undervalued.
The current stock price of zł0.17 is trading 28.5% below its estimated GF Value™ of zł0.24.
GuruFocus considers MedApp to be Modestly Undervalued.
Key valuation signals for WAR:MDA:
EV-to-EBITDA: 46.98 (176% above median its 10-year median of 17.03)
GF Value™: zł0.24 vs. price of zł0.17 (28.5% below fair value)
Industry Position: 330.2% above the Healthcare Providers & Services median (#468 of 510)
No single metric tells the full story. See the WAR:MDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDA has been successfully added to your 
